Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.36 |
| ▸ | ACHE | P22303 | 6/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL29642024 | 1.00 | GPR3 (0.48) | GPR3PTPN1CA1CA2CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL596729 | 0.93 | GPR3 (0.48) | GPR3PTPN1CA1CA2CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL10579458 | 0.93 | GPR3 (0.48) | GPR3PTPN1CA1CA2CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL25292546 | 0.89 | GPR3 (0.48) | GPR3PTPN1CA1CA2CA7 | |
| Trifluoromethanesulfonic Acid SCHEMBL164548 | 0.89 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL6478953 | 0.89 | CA1 (0.44) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL16829697 | 0.86 | CA1 (0.41) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL25255863 | 0.82 | CA1 (0.44) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL23430060 | 0.82 | CA1 (0.44) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL25301943 | 0.82 | CA1 (0.44) | GPR3PTPN1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 770 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115716805-B | Asymmetric catalytic synthesis method of chiral pyrazolone derivative containing propargyl alcohol structural fragment | 重庆医科大学 | 2024-05-07 | — | — | CN | claimed |
| EP-3956321-B1 | PROCESS FOR PREPARING AXITINIB, PROCESS FOR PURIFYING THE INTERMEDIATE 2-((3-IODO-1H-INDAZOL-6-YL)THIO)-N-METHYLBENZAMIDE, PROCESS FOR PURIFYING AXITINIB VIA THE AXITINIB HCL SALT, SOLID FORM OF THE AXITINIB HCL SALT | SYNTHON BV (NL) | 2024-03-20 | — | — | EP | claimed |
| CN-113444057-B | Single chiral arm aminophenol sulfonamide ligand and application thereof in asymmetric catalysis | 重庆医科大学 | 2023-06-20 | — | — | CN | claimed |
| US-20220389310-A1 | LUMINESCENT MATERIALS AND METHODS THEREOF | UNIVERSITY OF WASHINGTON (US) | 2022-12-08 | — | — | US | claimed |
| CN-113214069-B | Chiral 10-propargyl anthrone compound and synthetic method thereof | 华中师范大学 | 2022-07-08 | — | — | CN | claimed |
| EP-3956321-A1 | PROCESS FOR PREPARING AXITINIB, PROCESS FOR PURIFYING THE INTERMEDIATE 2-((3-IODO-1H-INDAZOL-6-YL)THIO)-N-METHYLBENZAMIDE, PROCESS FOR PURIFYING AXITINIB VIA THE AXITINIB HCL SALT, SOLID FORM OF THE AXITINIB HCL SALT | Synthon B.V. (NL) | 2022-02-23 | — | — | EP | claimed |
| WO-2021062035-A1 | LUMINESCENT MATERIALS AND METHODS THEREOF | UNIVERSITY OF WASHINGTON (US) | 2021-04-01 | — | — | WO | claimed |
| WO-2020212253-A1 | PROCESS FOR PREPARING AXITINIB, PROCESS FOR PURIFYING THE INTERMEDIATE 2-((3-IODO-1H-INDAZOL-6-YL)THIO)-N-METHYLBENZAMIDE, PROCESS FOR PURIFYING AXITINIB VIA THE AXITINIB HCL SALT, SOLID FORM OF THE AXITINIB HCL SALT | SYNTHON B.V. (NL) | 2020-10-22 | — | — | WO | claimed |
| EP-2460789-B1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-04-19 | — | — | EP | claimed |
| EP-2855419-B1 | NEW INDANYLOXYPHENYLCYCLOPROPANECARB OXYLIC ACIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-03-01 | — | — | EP | claimed |
| US-8633182-B2 | Indanyloxyphenylcyclopropanecarboxylic acids | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | claimed |
| US-20130324514-A1 | INDANYLOXYPHENYLCYCLOPROPANECARBOXYLIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-05 | — | — | US | claimed |
| EP-2460789-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2012-06-06 | — | — | EP | claimed |
| US-20120123154-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-17 | — | — | US | claimed |
| EP-2245020-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | claimed |
| WO-2009086163-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | claimed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | claimed |
| US-4948904-A | REACTING HYDROXYPHTHALIC ANHYDRIDE WITH BROMOPHTHALIC OR FLUOROPHTHALIC ANHYDRIDE IN PRESENCE OF COPPER CATALYST | OCCIDENTAL CHEMICAL CORPORATION (US) | 1990-08-14 | — | — | US | claimed |
| US-4946985-A | REACTING A HALOPHTHALIC ANHYDRIDE WITH WATER AND ALKALI METAL COMPOUND; COPPER CATALYST | OCCIDENTAL CHEMICAL CORPORATION (US) | 1990-08-07 | — | — | US | claimed |
| US-4689427-A | Hydroquinone derivatives useful in the production of vitamin E | HOFFMANN-LA ROCHE INC. (US) | 1987-08-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | NMUR1, NMUR2, PAM | GPR3 302/4885PTPN1 1725/4885CA1 1235/4885 |
| US-20130324514-A1 | INDANYLOXYPHENYLCYCLOPROPANECARBOXYLIC ACIDS | GPR119, GPR65, INSR | GPR3 22/4885PTPN1 2123/4885CA1 3467/4885 |
| US-20120123154-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | AKR7A2, AOC2, CBR1 | GPR3 2107/4885PTPN1 4606/4885CA1 1446/4885 |
| US-20220389310-A1 | LUMINESCENT MATERIALS AND METHODS THEREOF | TYR, GSTA2, CYBA | GPR3 2806/4885PTPN1 4329/4885CA1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.